

Roberta Sanfilippo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7039002/publications.pdf>

Version: 2024-02-01

49
papers

3,476
citations

218677

26
h-index

206112

48
g-index

49
all docs

49
docs citations

49
times ranked

3947
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment strategies and outcomes of primary Myxofibrosarcomas in a large patients cohort. <i>European Journal of Surgical Oncology</i> , 2022, 48, 1723-1729.	1.0	10
2	Defining the role of neoadjuvant systemic therapy in high-risk retroperitoneal sarcoma: A multi-institutional study from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group. <i>Cancer</i> , 2021, 127, 729-738.	4.1	30
3	Unmet Medical Needs and Future Perspectives for Leiomyosarcoma Patients: A Position Paper from the National Leiomyosarcoma Foundation (NLMSF) and Sarcoma Patients EuroNet (SPAEN). <i>Cancers</i> , 2021, 13, 886.	3.7	17
4	Trabectedin for Patients with Advanced Soft Tissue Sarcoma: A Non-Interventional, Retrospective, Multicenter Study of the Italian Sarcoma Group. <i>Cancers</i> , 2021, 13, 1053.	3.7	15
5	Selinexor versus doxorubicin in dedifferentiated liposarcoma PDXs: evidence of greater activity and apoptotic response dependent on p53 nuclear accumulation and survivin down-regulation. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 83.	8.6	11
6	Impact of Pathological Stratification on the Clinical Outcomes of Advanced Well-Differentiated/Dedifferentiated Liposarcoma Treated with Trabectedin. <i>Cancers</i> , 2021, 13, 1453.	3.7	12
7	Mechanisms of responsiveness to and resistance against trabectedin in murine models of human myxoid liposarcoma. <i>Genomics</i> , 2021, 113, 3439-3448.	2.9	2
8	Italian consensus conference on management of uterine sarcomas on behalf of S.I.G.O. (Società Italiana di Ginecologia Oncologica). <i>Journal of Cellular Biochemistry</i> , 2021, 122, 100-107.	2.8	21
9	Establishment and characterisation of a new patient-derived model of myxoid liposarcoma with acquired resistance to trabectedin. <i>British Journal of Cancer</i> , 2019, 121, 464-473.	6.4	7
10	Trabectedin and Radiotherapy in Soft Tissue Sarcoma (TRASTS): Results of a Phase I Study in Myxoid Liposarcoma from Spanish (GEIS), Italian (ISC), French (FSG) Sarcoma Groups. <i>EclinicalMedicine</i> , 2019, 9, 35-43.	7.1	49
11	Combination of PPAR β Agonist Pioglitazone and Trabectedin Induce Adipocyte Differentiation to Overcome Trabectedin Resistance in Myxoid Liposarcomas. <i>Clinical Cancer Research</i> , 2019, 25, 7565-7575.	7.0	15
12	Medical Therapy in Retroperitoneal Sarcomas. <i>Updates in Surgery Series</i> , 2019, , 133-141.	0.1	0
13	A phase II randomised (calibrated design) study on the activity of the single-agent trabectedin in metastatic or locally relapsed uterine leiomyosarcoma. <i>British Journal of Cancer</i> , 2018, 119, 565-571.	6.4	15
14	High-Dose Ifosfamide Chemotherapy in a Series of Patients Affected by Myxoid Liposarcoma. <i>Sarcoma</i> , 2017, 2017, 1-5.	1.3	6
15	Activity of anthracycline- and ifosfamide-based chemotherapy in a series of patients affected by advanced myxofibrosarcoma. <i>Clinical Sarcoma Research</i> , 2017, 7, 16.	2.3	20
16	Vascular resection en-bloc with tumor removal and graft reconstruction is safe and effective in soft tissue sarcoma (STS) of the extremities and retroperitoneum. <i>Surgical Oncology</i> , 2016, 25, 125-131.	1.6	41
17	Antiangiogenic activity of trabectedin in myxoid liposarcoma: Involvement of host TIMP1 and TIMP2 and tumor thrombospondin1. <i>International Journal of Cancer</i> , 2015, 136, 721-729.	5.1	50
18	Health-related quality of life results from PALETTE: A randomized, double-blind, phase 3 trial of pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or after prior chemotherapy: a European Organization for research and treatment of cancer soft tissue and bone sarcoma group global network study (EORTC 62072). <i>Cancer</i> , 2015, 121, 2933-2941.	4.1	72

#	ARTICLE	IF	CITATIONS
19	Long-term morbidity after multivisceral resection for retroperitoneal sarcoma. <i>British Journal of Surgery</i> , 2015, 102, 1079-1087.	0.3	43
20	Trabectedin in advanced synovial sarcomas. <i>Anti-Cancer Drugs</i> , 2015, 26, 678-681.	1.4	44
21	Myogenic Differentiation and Histologic Grading Are Major Prognostic Determinants in Retroperitoneal Liposarcoma. <i>American Journal of Surgical Pathology</i> , 2015, 39, 383-393.	3.7	101
22	Personalizing the Approach to Retroperitoneal Soft Tissue Sarcoma: Histology-specific Patterns of Failure and Postrelapse Outcome after Primary Extended Resection. <i>Annals of Surgical Oncology</i> , 2015, 22, 1447-1454.	1.5	152
23	Retrospective quality control review of FDG scans in the imaging sub-study of PALETTE EORTC 62072/VEG110727: a randomized, double-blind, placebo-controlled phase III trial. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 848-857.	6.4	25
24	BRCA1 haplotype and clinical benefit of trabectedin in soft-tissue sarcoma patients. <i>British Journal of Cancer</i> , 2015, 112, 688-692.	6.4	18
25	Correlation between radiological assessment and histopathological diagnosis in retroperitoneal tumors: Analysis of 291 consecutive patients at a tertiary reference sarcoma center. <i>European Journal of Surgical Oncology</i> , 2014, 40, 1662-1670.	1.0	36
26	High-dose continuous-infusion ifosfamide in advanced well-differentiated/dedifferentiated liposarcoma. <i>Clinical Sarcoma Research</i> , 2014, 4, 16.	2.3	44
27	Mode of action of trabectedin in myxoid liposarcomas. <i>Oncogene</i> , 2014, 33, 5201-5210.	5.9	111
28	Preoperative chemo-radiation therapy for localised retroperitoneal sarcoma: A phase II study from the Italian Sarcoma Group. <i>European Journal of Cancer</i> , 2014, 50, 784-792.	2.8	80
29	Identification of a gene expression driven progression pathway in myxoid liposarcoma. <i>Oncotarget</i> , 2014, 5, 5965-5977.	1.8	16
30	Anthracycline-based chemotherapy in extraskeletal myxoid chondrosarcoma: a retrospective study. <i>Clinical Sarcoma Research</i> , 2013, 3, 16.	2.3	34
31	In vitro and in silico studies of MDM2/MDMX isoforms predict Nutlin-3A sensitivity in well/de-differentiated liposarcomas. <i>Laboratory Investigation</i> , 2013, 93, 1232-1240.	3.7	17
32	Role of Macrophage Targeting in the Antitumor Activity of Trabectedin. <i>Cancer Cell</i> , 2013, 23, 249-262.	16.8	721
33	The intriguing patterns of tumor response to trabectedin. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 21-24.	2.4	6
34	Embryonal Rhabdomyosarcoma of the Uterine Cervix in Adults. <i>Journal of Lower Genital Tract Disease</i> , 2013, 17, e12-e17.	1.9	15
35	Myxoid liposarcoma and the mammalian target of rapamycin pathway. <i>Current Opinion in Oncology</i> , 2013, 25, 379-383.	2.4	13
36	Gemcitabine in advanced angiosarcoma: a retrospective case series analysis from the Italian Rare Cancer Network. <i>Annals of Oncology</i> , 2012, 23, 501-508.	1.2	130

#	ARTICLE	IF	CITATIONS
37	Frontline extended surgery is associated with improved survival in retroperitoneal low- to intermediate-grade soft tissue sarcomas. <i>Annals of Oncology</i> , 2012, 23, 1067-1073.	1.2	180
38	Venous thromboembolism is a relevant and underestimated adverse event in cancer patients treated in phase I studies. <i>British Journal of Cancer</i> , 2012, 107, 612-616.	6.4	4
39	Uterine sarcomas: a multidisciplinary challenge. <i>European Journal of Cancer</i> , 2011, 47, S326-S327.	2.8	1
40	Trabectedin in advanced uterine leiomyosarcomas: A retrospective case series analysis from two reference centers. <i>Gynecologic Oncology</i> , 2011, 123, 553-556.	1.4	68
41	Myxofibrosarcoma: Prognostic Factors and Survival in a Series of Patients Treated at a Single Institution. <i>Annals of Surgical Oncology</i> , 2011, 18, 720-725.	1.5	199
42	<i>ERCC5</i> , <i>XPG</i> , <i>ERCC1</i> , and <i>BRCA1</i> gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma. <i>Cancer</i> , 2011, 117, 3445-3456.	4.1	57
43	Trabectedin therapy for sarcomas. <i>Current Opinion in Oncology</i> , 2010, 22, 342-346.	2.4	40
44	Novel Models of Myxoid Liposarcoma Xenografts Mimicking the Biological and Pharmacologic Features of Human Tumors. <i>Clinical Cancer Research</i> , 2010, 16, 4958-4967.	7.0	24
45	Functional Mapping of Receptor Tyrosine Kinases in Myxoid Liposarcoma. <i>Clinical Cancer Research</i> , 2010, 16, 3581-3593.	7.0	40
46	Antitumor and Anti-inflammatory Effects of Trabectedin on Human Myxoid Liposarcoma Cells. <i>Cancer Research</i> , 2010, 70, 2235-2244.	0.9	251
47	Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series. <i>Annals of Oncology</i> , 2009, 20, 1439-1444.	1.2	112
48	Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. <i>Lancet Oncology</i> , The, 2007, 8, 595-602.	10.7	416
49	Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma. <i>European Journal of Cancer</i> , 2006, 42, 1484-1490.	2.8	85